Soreide Law Group has been contacted by clients who purchased Onconova Therapeutics, Inc. (ONTX) and experienced significant stock losses through the sale of the stock brokers at Laidlaw and Company. Laidlaw is listed on their website as the “Sole Book Runner” from the April 2017 offering. Securities that are newly issued are often more volatile than the more established companies, and if you, as the investor, were not looking to speculate, this could have been a highly unsuitable recommendation given to you by your broker from Laidlaw and Company.
According to Yahoo Finance, Onconova Therapeutics, Inc. (ONTX), a clinical-stage biopharmaceutical company, focusing on discovering and developing small molecule product candidates to treat cancer. The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
In April of 2017, Onconova Therapeutics, Inc. (ONTX) was trading around 2.7, and today it is trading at approximately 0.37. The 52-week change is -81.89%%.
On Laidlaw and Company’s website, the following information on their company is given:”Our team of bankers’ focus on the healthcare industry and the depth of their experience allows them to provide comprehensive knowledge of both the industry and the markets.”
If you’ve experienced financial losses in Onconova Therapeutics, Inc. (ONTX) due to the recommendations of Laidlaw and Company’s securities brokers, call Soreide Law Group for a no cost consultation with an experienced securities lawyer regarding the possibility of recovering your significant financial losses through a FINRA arbitration at: 888-760-6552.
Soreide Law Group represents our clients nationwide before FINRA. We operate on a contingency fee basis, no fee if no recovery.